Catarina Tavares

Prof. Dr. Catarina Tavares

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
CTCatarina Tavares
Catarina Tavares
Catarina EloyCatarina Eloy
Catarina Eloy
MMMiguel Melo
Miguel Melo
ARAdriana Gaspar da Rocha
Adriana Gaspar da Rocha
APAna Pestana
Ana Pestana
Paula SoaresPaula Soares
Paula Soares
The mammalian target of rapamycin (mTOR) pathway is overactivated in thyroid cancer (TC). We previously demonstrated that phospho-mTOR expression is associated with tumor aggressiveness, therapy resistance, and lower mRNA expression of SLC5A5 in papillary thyroid carcinoma (PTC), while phospho-S6 (mTORC1 effector) expression was associated with less aggressive clinicopathological features. The distinct behavior of the two markers led us to hypothesize that mTOR activation may be contributing to a preferential activation of the mTORC2 complex. To approach this question, we performed immunohistochemistry for phospho-AKT Ser473 (mTORC2 effector) in a series of 182 PTCs previously characterized for phospho-mTOR and phospho-S6 expression. We evaluated the impact of each mTOR complex on SLC5A5 mRNA expression by treating cell lines with RAD001 (mTORC1 blocker) and Torin2 (mTORC1 and mTORC2 blocker). Phospho-AKT Ser473 expression was positively correlated with phospho-mTOR expression. Nuclear expression of phospho-AKT Ser473 was significantly associated with the presence of distant metastases. Treatment of cell lines with RAD001 did not increase SLC5A5 mRNA levels, whereas Torin2 caused a ~6 fold increase in SLC5A5 mRNA expression in the TPC1 cell line. In PTC, phospho-mTOR activation may lead to the activation of the mTORC2 complex. Its downstream effector, phospho-AKT Ser473, may be implicated in distant metastization, therapy resistance, and downregulation of SLC5A5 mRNA expression.

Verified
Journal Article
Open access
PDF file
LFLuciana Ferreira
Luciana Ferreira
Raquel  T. LimaRaquel T. Lima
Raquel T. Lima
ABAna Clara Santos da Fonseca Bastos
Ana Clara Santos da Fonseca Bastos
ASAndreia Silva
Andreia Silva
CTCatarina Tavares
Catarina Tavares
Paula SoaresPaula Soares
Paula Soares
Osteopontin (OPN) spliced variants (OPN-SV: OPNa, OPNb, and OPNc) are aberrantly expressed in tumors and frequently associated with cancer progression. This holds true for papillary thyroid carcinoma (PTC), which is the most common type of thyroid cancer (TC). PTC often presents with desmoplasia and dystrophic calcification, including psammoma bodies (PB). This work aimed to investigate total OPN (tOPN) and OPN-SV expression and their association with the presence of PB in the PTC classical variants (cPTC), as well as the involvement of OPN-SV in matrix calcification of TC cell lines. We found that cPTC samples presenting PB showed higher OPN expression levels. In TC cell lines, OPNa overexpression promotes higher matrix calcification and collagen synthesis when compared to that of clones overexpressing OPNb or OPNc. In response to OPN knockdown, calcification was inhibited, paralleled with the downregulation of calcification markers. In conclusion, our data evidenced that OPN expression is associated with the presence of PB in cPTC samples. Among the OPN-SV, OPNa is the main contributor to matrix calcification in tested TC cells, providing clues to a better understanding on the biology and ethiopathogenesis of the calcification process in TC cells.

3 May 2017 in Endocrine Abstracts
Verified
Journal Article
Closed access
CTCatarina Tavares
Catarina Tavares
MCMaria João Coelho
Maria João Coelho
Catarina EloyCatarina Eloy
Catarina Eloy
MMMiguel Melo
Miguel Melo
RDRocha Adriana Gaspar da
Rocha Adriana Gaspar da
Paula SoaresPaula Soares
Paula Soares
Thyroid cancer therapy is based on surgery followed by radioiodine treatment of tumor remnants and metastases. The incorporation of radioiodine by cancer cells is mediated by sodium iodide symporter (NIS), normally present in thyroid follicular cells’ membrane. We studied the expression of NIS in a series of 229 thyroid primary tumors using real time PCR and immunohistochemistry, and searched for possible associations between NIS expression and clinicopathological features, molecular data, response to therapy and prognosis. NIS mRNA levels were significantly lower in carcinomas than in normal adjacent thyroid; carcinomas from males or with vascular invasion presented significantly less NIS mRNA expression than carcinomas from women and non invasive carcinomas. BRAFV600E tumors and those presenting extrathyroidal extension had a tendency to display lower NIS mRNA expression than tumors BRAFWT and no extrathyroidal extention. Regarding immunohistochemistry, only 12/211 of the cases demonstrated NIS in the basolateral membrane of tumor cells; these cases showed variable outcomes concerning therapy response and prognosis. All but one of the aforementioned cases were wild type for BRAF, NRAS and TERT promoter mutations. NIS immunohistochemical expression in primary tumors did not predict tumor behavior or response to therapy. NIS mRNA expression was more informative of tumor aggressiveness than NIS protein expression. In order to validate our data we also searched possible associations between NIS mRNA expression and clinicopathological and molecular features on 378 primary papillary thyroid carcinomas of the TCGA database. Further studies are needed to confirm the association observed between the presence of the oncogenic mutations (BRAF, NRAS and TERT promoter) and both lower mRNA expression and diminished membrane targeting of NIS protein.

24 June 2025 in Veterinary Sciences
Verified
Journal Article
Open access
PDF file
AMAlexandra Filipa Rocha Monteiro
Alexandra Filipa Rocha Monteiro
Tiago Bordeira GasparTiago Bordeira Gaspar
Tiago Bordeira Gaspar
IBInês Borges
Inês Borges
Sule CANBERKSule CANBERK
Sule CANBERK
MPMafalda Pinto
Mafalda Pinto
CTCatarina Tavares
Catarina Tavares
Thyroid tumors are common in humans and cats, occurring most commonly as benign lesions, whereas thyroid carcinoma is barely detected in both species. Determining the mutational status of MAPK-related genes (BRAF, NRAS, HRAS, and KRAS) and the activation status of MAPK and mTOR pathways is crucial for establishing the diagnosis, treatment, and prognosis of human patients. So far, the role of such players in feline thyroid tumorigenesis remains underexplored. This study aims to elucidate the presence and implications of potential shared molecular mechanisms between human and feline thyroid tumors. Fifteen formalin-fixed paraffin-embedded feline thyroid epithelial tumors (four tumors with atypia and 11 with no atypia) were collected to perform mutational and immunohistochemical analyses. Sanger sequencing targeting human homologous hotspots revealed no mutations in BRAF (human codon 600) or RAS (human codon 61) regions. A KRAS missense mutation (p.Gln232His) was identified in two tumors with no atypia of follicular pattern (2/15, 13%). Regardless of the mutational status, pERK (Thr202/Ty204) was immuno-expressed in 10/11 (91%), pS6 (Ser235/236) in 100%, and pAKT (Ser473) in 8/11 (73%) of the tumors with no atypia. The expression patterns of pERK, pS6, and pAKT and their associations with clinical-pathological features seem to mirror the progression dynamics observed in human thyroid tumorigenesis. pAKT expression was associated with the presence of multiple tumor foci within the same thyroid lobe, suggesting its potential as a marker of aggressiveness in feline thyroid tumors. This study introduces cats as potential animal models for human thyroid tumorigenesis, with further research required to confirm such potential.

11 February 2016 in Endocrine Abstracts
Verified
Journal Article
Closed access
CTCatarina Tavares
Catarina Tavares
MCMaria Coelho
Maria Coelho
MMMiguel Melo
Miguel Melo
ARAdriana Rocha
Adriana Rocha
APAna Pestana
Ana Pestana
Paula SoaresPaula Soares
Paula Soares
Background: Mammalian target of rapamycin (mTOR) is a downstream effector of the PI3K/AKT pathway. It can be activated by diverse stimuli, such as growth factors, nutrients, energy, stress signals and signaling pathways such as PI3K, MAPK and AMPK, in order to control cell growth, proliferation and survival. The active form of mTOR (pmTOR) may form two distinct complexes: mTORC1 that activates S6K1 and 4EBP1 which are involved in mRNA translation; and mTORC2 that activates PKC-α and AKT, regulating actin cytoskeleton organization, cell migration and survival1. mTOR deregulation is observed in multiple cancers2. In papillary thyroid carcinoma (PTC), mTOR pathway was reported to be overactivated in PTC3, particularly in those with BRAF mutation compared to BRAF wt4. Sodium iodide symporter (NIS) is a transmembrane glycoprotein that transports iodine from bloodstream to the interior of follicular cells to participate in the normal process of thyroid hormone synthesis5. Thyroid cancer therapy is based on surgery followed by 131I to treat possible tumor remnants and metastases. NIS is a vital protein in this process because it transports the radioactive iodine to the interior of cancer cells, resulting in their death. Approximately 20% of well differentiated thyroid tumors lose NIS expression becoming refractory to therapy6. The mechanisms of loss of NIS expression remain poorly understood, but it has been described that mTOR pathway activation decreases iodine uptake by thyrocytes5 and that inhibition of the pathway in thyroid tumor cell lines increases differentiation resulting in higher iodine uptake6. Aim and methods: In order to study mTOR pathway status and possible associations with clinicopathological (age, gender, tumor capsule, tumor capsule invasion, extrathyroidal invasion, multifocality, lymphocytic infiltration, lymph node metastases, vascular invasion, status of tumor margins, staging, distant metastases, persistence of disease) and molecular features (BRAF, NRAS, TERT promoter mutations, RET/PTC rearrangements) as well as with NIS expression, we studied by immunohistochemistry pmTOR and pS6 in a series of 192 PTCs with detailed clinicopathological informations, addressing NIS expression in 44 of them by real time PCR. Results: pmTOR expression was significantly higher in PTCs presenting absence of capsule, distant metastases and persistence of disease. Furthermore, pmTOR expression was significantly correlated with higher number of 131I therapies, higher cumulative dosis and with lower NIS expression. Additionally, pmTOR revealed to be an independent risk factor for distant metastases. The expression of pS6 was significantly associated with presence of capsule and absence of extrathyroid extension and of lymphocytic infiltration, and with BRAF wt status. There was no correlation between pmTOR and pS6 expression. Conclusions: Despite pS6 being a downstream effector of pMTOR in the mTOR pathway, we observed, in this work, a different behavior of both markers. pmTOR expression is associated with aggressiveness and worse prognosis, while pS6 associates with less aggressive clinicopathological features. The discordant results obtained with both markers and the lack of correlation of their expression, lead us to hypothesize that mTOR activation preferentially induces the formation of mTORC2 complex, activating other downstream effectors than pS6. Further studies are needed to confirm this hypothesis, namely regarding the dissection of which mTOR complex (1 or 2) is being preferentially activated in PTCs, so that we can use the most appropriate pharmacological strategy to block the pathway. Such blockage may be very important to overcome tumor progression and refractoriness to radioactive iodine therapy. References 1. Populo H, Lopes JM & Soares P. The mTOR signalling pathway in human cancer. International Journal of Molecular Sciences 2012 13 1886–1918. 2. Chiarini F, Evangelisti C, McCubrey JA & Martelli AM. Current treatment strategies for inhibiting mTOR in cancer. Trends in Pharmacological Sciences 2015 36 124–135. 3. Kouvaraki MA, Liakou C, Paraschi A, Dimas K, Patsouris E, Tseleni-Balafouta S, Rassidakis GZ & Moraitis D. Activation of mTOR signaling in medullary and aggressive papillary thyroid carcinomas. Surgery 2011 150 1258–1265. 4. Faustino A, Couto JP, Populo H, Rocha AS, Pardal F, Cameselle-Teijeiro JM, Lopes JM, Sobrinho-Simoes M & Soares P. mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 2012 97 E1139–1149. 5. de Souza EC, Padron AS, Braga WM, de Andrade BM, Vaisman M, Nasciutti LE, Ferreira AC & de Carvalho DP. MTOR downregulates iodide uptake in thyrocytes. Journal of Endocrinology 2010 206 113–120. 6. Plantinga TS, Heinhuis B, Gerrits D, Netea MG, Joosten LA, Hermus AR, Oyen WJ, Schweppe RE, Haugen BR, Boerman OC et al. mTOR Inhibition promotes TTF1-dependent redifferentiation and restores iodine uptake in thyroid carcinoma cell lines. Journal of Clinical Endocrinology and Metabolism 2014 99 E1368–1375.

11 February 2016 in Endocrine Abstracts
Verified
Journal Article
Closed access
LFLuciana Ferreira
Luciana Ferreira
CTCatarina Tavares
Catarina Tavares
APAna Pestana
Ana Pestana
CLCatarina Leite
Catarina Leite
Catarina EloyCatarina Eloy
Catarina Eloy
Paula SoaresPaula Soares
Paula Soares
Osteopontin (OPN) is a matricellular protein highly expressed in cancer cells, which is able to modulate tumorigenesis and metastasis in several malignancies, including follicular cell-derived thyroid cancers (TC). OPN is one of the gene products aberrantly expressed in TC, but the contribution of each OPN isoform (OPNi), named as OPNa, OPNb and OPNc, is currently unknown. This study aims to analyze the expression profile of OPNi in TC tissue samples, correlate its expression with molecular and clinicopathologic features, and evaluate the role of OPNi in TC cell lines. The expression profiles of OPNi in TC cell lines and in thyroid tissue samples were evaluated by q-RT-PCR and immunohistochemistry. In order to address the putative roles of OPNi in TC, we overexpressed OPNi in TC cell lines. c643 and 8505c cells were transfected with vectors containing OPNi as well as empty vector, and stable overexpressing clones were selected with geneticin. Functional assays (proliferation, migration, motility, gelatin zymography and invasion) were also performed. We found that the OPNa and the OPNb isoforms are expressed in higher levels in classic papillary thyroid carcinoma (cPTC) samples than in non-tumoral thyroid, adenomas and follicular thyroid carcinoma tissues. Conversely, OPNc isoform transcript levels are similar among samples from the aforementioned pathologies. In cPTC samples, high OPNa and OPNb expression levels were significantly associated with higher tumor size, presence of vascular invasion and BRAFV600E mutation. In eight distinct TC cell lines, we observed differential expression of the three OPNi, of which cell line c643 expressed the lower levels of OPNi. Higher proliferation, migration and motility were associated with c643 and 8505c cells overexpressing OPNa. In both cell lines overexpressing OPNa, we observed an increase of matrix metalloproteinase 2 in the extracellular medium. Further, in in vivo CAM assay we found that cells overexpressing OPNa are significantly more invasive when compared to the control cells. Taken together, our data indicate that both OPNa and OPNb are overexpressed in cPTC samples and OPNa is the isoform that is significantly associated to promotion of cell growth, migration, motility and invasion in TC cells.